Synthetic Circuits Reveal the Key to Rewinding the Cellular Clock

Using a circuit-based system, scientists determined the ideal transcription factor levels to promote the successful reprogramming of fibroblasts into induced pluripotent stem cells.

Written byCharlene Lancaster, PhD
| 4 min read
A person moving the hands of a vintage clock backwards.
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Most people wonder how their lives would change if they could turn back time and remake past decisions. While a seemingly impossible feat, stem cell biologists Kazutoshi Takahashi and Shinya Yamanaka at Kyoto University first turned back the cellular clock in 2006.1 By overexpressing four transcription factors in fully differentiated fibroblasts, Takahashi and Yamanaka reprogrammed the cells to a pluripotent state and called them induced pluripotent stem cells (iPSC).

Although researchers employ iPSC in the laboratory and the clinic, scientists struggle to efficiently produce large quantities of iPSC.2 “Reprogramming is still very inefficient,” said Thorsten Schlaeger, a stem cell biologist at the Boston Children’s Hospital. “It is still not fully understood why 98 or 99.9 percent of the cells do not end up reprogramming into iPSC.” In a recently published Science Advances paper, Schlaeger and his team developed a system for tracking the fate of cells with different transcription factor expression dynamics during reprogramming.3 These findings will enable researchers in the field to improve iPSC yield.

Scientists suspected that the heterogeneity in reprogramming outcomes results from variations in the levels and durations of transcription factors’ expression. Consequently, several research groups have attempted to correlate the success of reprogramming to the levels of the octamer-binding transcription factor 4 (OCT4), which is one of Takahashi and Yamanaka’s transcription factors that is essential for the reprogramming process. However, these studies used population-based measurements and failed to consider the contribution of endogenous OCT4 to reprogramming.

Compelled to overcome these limitations, Schlaeger’s coauthor Domitilla Del Vecchio, a discipline-straddling mechanical engineer at the Massachusetts Institute of Technology, developed an innovative OCT4 expression system. “The idea really was to try to use a more sophisticated way of overexpressing transcription factors to reprogram stem cells,” Del Vecchio recalled.

Del Vecchio’s team designed a synthetic gene circuit to ectopically overexpress a fluorescently-tagged version of the OCT4 transcription factor, while simultaneously blocking the expression of the endogenous OCT4 through microRNA. This allowed the researchers to control the total OCT4 protein levels within the cell and quantify them by measuring the fluorescence. Additionally, the ectopic OCT4 gene was controlled by an inducible and noisy promoter, which meant that the system generated variability in the expression of the OCT4 conjugate and a broad range of trajectories to assess, such as cells that maintained high OCT4 expression throughout reprogramming or those whose expression decreased over time.

Photos of the authors of the study: Thorsten Schlaeger (left) and Domitilla Del Vecchio (right).
Thorsten Schlaeger and Domitilla Del Vecchio developed a synthetic gene circuit-based system that allowed them to control and monitor the total OCT4 protein levels within fibroblasts during reprogramming.
Thorsten Schlaeger and Domitilla Del Vecchio

To determine which OCT4 trajectories successfully reprogrammed human dermal fibroblasts into iPSC, Del Vecchio, Schlaeger, and their team transduced the cells with lentiviral vectors encoding their OCT4 trajectory generator and followed the levels of fluorescently-tagged OCT4 proteins within the cells over time through imaging. The researchers then fixed the resulting cell colonies and immunostained them for two pluripotent stem cell surface markers.

They observed that the colonies fell into three categories: type I colonies were positive for only one of the surface markers; type II colonies showed the exact opposite staining pattern from type I; and type III colonies were positive for both markers. They considered cells within type III colonies as iPSC and categorized the cells within type I and II colonies as incompletely reprogrammed. Despite these differences, cells in all three colony types stably expressed supraphysiological levels of OCT4 during reprogramming, indicating that successfully reprogramming human dermal fibroblasts into iPSC requires consistently high levels of the OCT4 transcription factor. But this parameter alone is not sufficient to promote iPSC generation.


“The paper is innovative in a technical sense. It is consistent with work that has been done showing that elevated levels of OCT4 are important for the reprogramming process,” said Dean Tantin, a geneticist at the University of Utah, who was not involved in the study.

Although Tantin thought Del Vecchio’s system presented a clever way to directly examine total OCT4 protein levels within live cells, he suggested that examining protein levels alone may not convey the whole story. “The level of a protein based on a fluorescent marker is not the same as the activity of a protein—its ability to bind DNA [or] its ability to regulate transcription once it binds," he noted. "So, I think where the field needs to go now is [to find out] how OCT4 activity is really dynamically regulated during [reprogramming].” he noted. Building on this idea, Tantin and his team recently determined that OCT4 activity during reprogramming and differentiation is redox-regulated, and he suspects that regulation of other reprogramming components will be of interest in the years to come.4

Del Vecchio hopes that her work will inspire other researchers to think beyond the standard methods they employ to dissect molecular pathways. “This study is showing how more sophisticated genetic engineering tools can be used in the context of a highly complex biological process and help you get information that will be difficult to get otherwise,” Del Vecchio said.

Schlaeger wants to leverage the knowledge gained in this study to develop off-the-shelf iPSC-based therapies, such as CAR T cells, and he believes that precision engineering will be the key to safely bringing these products to the clinic. “With the cells, we want to get to this precise control and that can only be done with complex genetic switches and circuits,” Schlaeger said.

Related Topics

Meet the Author

  • Charlene Lancaster, PhD

    Charlene earned her MSc and PhD in cell biology from the University of Toronto, where she studied how vitamins increase bone formation in osteoblast cell culture and how macrophages resolve phagosomes. She currently serves as an assistant science editor for The Scientist's creative services team.

    View Full Profile
Share
You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
Explore synthetic DNA’s many applications in cancer research

Weaving the Fabric of Cancer Research with Synthetic DNA

Twist Bio 
Illustrated plasmids in bright fluorescent colors

Enhancing Elution of Plasmid DNA

cytiva logo
An illustration of green lentiviral particles.

Maximizing Lentivirus Recovery

cytiva logo
Explore new strategies for improving plasmid DNA manufacturing workflows.

Overcoming Obstacles in Plasmid DNA Manufacturing

cytiva logo

Products

The Scientist Placeholder Image

Waters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

agilent-logo

Agilent Announces the Enhanced 8850 Gas Chromatograph

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies